- |||||||||| Journal: Development and Application of a Senolytic Predictor for Discovery of Novel Senolytic Compounds and Herbs. (Pubmed Central) - Jun 27, 2025
Additionally, voclosporin was found to extend the lifespan of C. elegans more effectively than metformin, demonstrating the value of our model for drug repurposing. This study not only provides an efficient framework for discovering novel senolytic agents, but also highlights the predicted novel senolytic compounds and herbs as valuable starting points for future research into senolytic drug development.
- |||||||||| Lupkynis (voclosporin) / Aurinia Pharma, cyclosporine / Generic mfg.
Journal: Voclosporin-induced gingival enlargement: A case report. (Pubmed Central) - Jun 26, 2025 The enlargement of the gums significantly improved once the drug was discontinued. This report highlights for the first time, to the authors' knowledge,
- |||||||||| Lupkynis (voclosporin) / Aurinia Pharma
Trial completion date, Trial primary completion date: VOCAL-EXT: Long-Term Voclosporin Treatment in Adolescent and Pediatric Subjects With Lupus Nephritis (clinicaltrials.gov) - Jun 18, 2025 P3, N=40, Enrolling by invitation, We will also explore real-world cases of refractory lupus nephritis and discuss practical examples of how the aforementioned therapies are being applied in clinical practice. Trial completion date: Sep 2026 --> Jun 2029 | Trial primary completion date: Jun 2026 --> Dec 2028
- |||||||||| Lupkynis (voclosporin) / Aurinia Pharma
Rates of sustained complete renal-response with long-term use of voclosporin in AURORA 2 () - Jun 9, 2025 - Abstract #UKKW2025UKKW_636; Consistent with using CRR as an efficacy endpoint in AURORA 1, more VCS- than control- treated patients achieved SCRR, despite nearly 40% of the analyzed study population being ineligible due to the voluntary nature of AURORA 2 participation. The stringency and potential utility of this new endpoint require further exploration.
- |||||||||| Lupkynis (voclosporin) / Aurinia Pharma
PREGNANCY OUTCOMES IN PATIENTS EXPOSED TO VOCLOSPORIN: A SUMMARY OF AVAILABLE DATA FROM CLINICAL TRIALS AND POST-MARKETING SOURCES () - May 28, 2025 - Abstract #EULAR2025EULAR_4224; P2, P3 Active LN in pregnancy is associated with an increased risk of adverse maternal and fetal outcomes, and observations from this limited cohort reflect the overall challenges faced by female patients of child-bearing age with active LN. The limited data presented here are insufficient to draw conclusions regarding the use of voclosporin during pregnancy, and additional research is needed to better characterize maternal and fetal outcomes following voclosporin exposure.
- |||||||||| Lupkynis (voclosporin) / Aurinia Pharma, Saphnelo (anifrolumab-fnia) / AstraZeneca
Journal: Combination Therapy With Voclosporin and Anifrolumab in Two Patients With Lupus Nephritis and Discoid Lupus Erythematosus. (Pubmed Central) - May 5, 2025 Therefore, it is critical to identify safe targets for lupus disease activity, minimizing drug toxicity and preventing damage accrual. We present two cases with disease features of discoid lupus erythematosus (DLE) and lupus nephritis (LN), who were treated safely and successfully with Voclosporin and Anifrolumab, resulting in disease remission without the use of oral steroids.
- |||||||||| ISS1.11 Multi-target treatments and a multidisciplinary approach: How they can improve care for patients with lupus nephritis (Hall E2) - Apr 15, 2025 - Abstract #ERA2025ERA_385;
The approval of belimumab and voclosporin represents a milestone in the management, and other substances such as obinutuzumab have met the primary endpoint of their approval trial and will likely be marketed soon...Management issues encountered by other specialities such as rheumatologists or dermatologists will be outlined and specific therapies approved for non-renal SLE, such as anifrolumab, will be discussed in this context.Besides treatment of active disease ("remission induction"), long-term prescription of immunosuppression is reality...While such an approach is invasive and often disregarded by affected patients, our symposium will outline that this is an essential point moving forward in the individualisation of therapy.In summary, relevant points for nephrologists are tackled from different perspectives in our symposium. These include the implementation of novel therapies in the management of SLE and LN, when referral to other specialities needs to be considered to optimise extra-renal disease manifestations and improve quality of life, and finally discussion around the ideal duration of therapies to prevent disease relapses and thereby worsening of chronic kidney disease.
- |||||||||| Benlysta (belimumab) / GSK, Lupkynis (voclosporin) / Aurinia Pharma
Review, Journal: Kidney transplantation in Lupus Nephritis: a comprehensive review of challenges and strategies. (Pubmed Central) - Mar 23, 2025 Current guidelines emphasize the importance of achieving disease quiescence before transplantation, while new evidence supports the benefits of preemptive transplantation and personalized immunosuppressive regimens in improving patient and graft survival. This review highlights the latest evidence and strategies for optimizing kidney transplantation outcomes in LN patients, focusing on timing, immunosuppression, and disease monitoring.
- |||||||||| Journal: A focused report on IFN-1 targeted therapies for lupus erythematosus. (Pubmed Central) - Mar 6, 2025
Daxdilimab was unsuccessful in its phase II trial...Anifrolumab binds to the IFN-I receptor, blocking the activity of all IFN-Is, and deucravacitinib reduces IFN-I by inhibiting TYK2, thereby interfering with downstream signaling. Therapies that target IFN-I represents a promising class of medications for SLE patients.
- |||||||||| bleomycin / Generic mfg., AUR300 / Aurinia Pharma
Preclinical, Journal: PET Imaging of CD206 Macrophages in Bleomycin-Induced Lung Injury Mouse Model. (Pubmed Central) - Feb 26, 2025 In contrast, the healthy mice exhibited no detectable CD206 staining, lower PET signals, and reduced radiopharmaceutical accumulation in lung tissues at the same timepoint. These findings suggest that both linear and cyclic [68Ga]Ga-RP832c may function as promising PET imaging agents for CD206 macrophages, and thereby a strategy to non-invasively explore the role of macrophages during fibrogenesis.
- |||||||||| Benlysta (belimumab) / GSK, Lupkynis (voclosporin) / Aurinia Pharma
Review, Journal: Ten tips in lupus nephritis management. (Pubmed Central) - Jan 28, 2025 Ironically, the increasing therapeutic options have resulted in uncertainties in deciding which medication, and which treatment regimen, is best for a patient. In this context, one needs to take into consideration the distinct characteristics and the risk profile of each patient, and adopt a holistic and long-term perspective, so that treatment can be personalized to achieve favourable clinical outcomes.
- |||||||||| Lupkynis (voclosporin) / Aurinia Pharma
Observational data, Journal: Exploring potential drug targets for SLE through Mendelian randomization and network pharmacology. (Pubmed Central) - Jan 18, 2025 Our integrative analysis suggested that levels of circulating PPP3CA; PPP3R1 had causal effects on SLE risk and served as potential treatment targets. Moreover, this study provides new evidence for Voclosporin as an SLE treatment through Mendelian randomization and Network pharmacology, and warrants further clinical investigation.
- |||||||||| Review, Journal: Novel therapies in SLE treatment: A literature review. (Pubmed Central) - Jan 16, 2025
In addition, several biological agents are targeting different cells or cytokines that are being evaluated in phase II and III clinical trials. Apart from that, experimental therapies such as targeting of plasma cells, chimeric antigen receptor T-cell therapy (CAR-T) or stem cell transplantation appear promising in the treatment of the severe forms of SLE.
- |||||||||| Benlysta (belimumab) / GSK, Lupkynis (voclosporin) / Aurinia Pharma, Rituxan (rituximab) / Roche
Navigating complexities in male paediatric-onset lupus: From macrophage activation syndrome and refractory lupus nephritis to CAR-T cell therapy () - Nov 8, 2024 - Abstract #BSRCBC2024BSR_CBC_33; He had multiple medications over the years, which were not well-tolerated: mycophenolate mophetil (gastrointestinal disturbance), azathioprine (low white cell count), and hydroxychloroquine (significant diarroea)...In the same year, while being on methotrexate, he developed class IV lupus nephritis (LN)...In May 2024, the patient was on mycophenolic acid 180 mg bd (maximum tolerated dose), Prednisolone 10 mg od, and Voclosporin 23.7 mg twice a day, and had 6-monthly Rituximab (last dose in February 2024)...Adding immunosuppresive medications, such as belimumab, or trying CAR-T cell therapy (phase I for LN) was offered...During the conference, we are looking forward to hearing from both paediatric and adult colleagues how they would manage this patient. We are also hoping the patient to have started on CAR-T cell therapy by the start of the conference, so we can present our experience with CAR-T cell therapy and in any case, to raise awareness about this new novel treatment which has the potential to revolutianise the treatment of rheumatic diseases.
- |||||||||| Review, Journal: JAK inhibitors in systemic lupus erythematosus: Translating pathogenesis into therapy. (Pubmed Central) - Oct 16, 2024
The efforts of the drug development programme in lupus have led to considerable growth in the last decade, owing to the approval of belimumab, anifrolumab, and voclosporin...Multiple JAKis are currently being investigated in SLE. This paper aims to summarize existing data coming from both clinical trials and case reports regarding the use of JAK inhibitors in SLE.
- |||||||||| Biomarker, Journal: Prognostic Factors for Mortality in Patients With Autoimmune Diseases Complicated by Pneumocystis Pneumonia. (Pubmed Central) - Sep 25, 2024
Additionally, the risk of mortality for PCP under the administration of new biological agents, such as anifrolumab, belimumab, and rituximab, or immunosuppressants, such as mycophenolate mofetil and voclosporin, should be evaluated. These findings can contribute to improving PCP prevention and treatment strategies in patients with autoimmune diseases, ultimately leading to better patient outcomes.
- |||||||||| Lupkynis (voclosporin) / Aurinia Pharma
Patient Reported Outcomes Analyses from AURORA 1 Clinical Trial: Lupus Impact Tracker and LupusPRO (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_3471; Significantly larger magnitude and clinically meaningful reductions in negative impacts of lupus on patients' daily lives were noted on the Lupus Impact Tracker among patients that attained CRR as compared to those that did not. LIT or LupusPRO HRQOL domains capture more proximal impacts of the disease or its treatments in clinical trials.
- |||||||||| Lupkynis (voclosporin) / Aurinia Pharma
Rates of Sustained Complete Renal Response with Long-term Use of Voclosporin in AURORA 2 (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_3457; Consistent with using CRR as an efficacy endpoint in AURORA 1, more VCS- than control-treated patients achieved SCRR, despite nearly 40% of the analyzed study population being ineligible due to the voluntary nature of AURORA 2 participation. The stringency and potential utility of this new endpoint require further exploration.This work was funded by Aurinia Pharmaceuticals Inc.
- |||||||||| Benlysta (belimumab) / GSK, Lupkynis (voclosporin) / Aurinia Pharma, Saphnelo (anifrolumab-fnia) / AstraZeneca
Prescribing Trends for Novel Treatments in Systemic Lupus from 2017 to 2022 (In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_3449; Our data suggests that Southern states have greater prescription rates of these medications, which, among other factors, may reflect regional variations in SLE prevalence. Interestingly, all claims for anifrolumab in 2021 came from the West, which may reflect factors such as different rates of marketing, information dissemination, etc.
|